
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 30, 2007 (May 23, 2007)



CHEMBIO DIAGNOSTIC, INC.

(Exact name of registrant as specified in its charter)

Nevada
(State or other
jurisdiction
of Incorporation)

0-30379
(Commission File Number)

88-0425691
(IRS Employer

Identification Number)

3661 Horseblock Road
Medford, NY 11763
(Address of principal executive offices)
631-924-1135
(Registrant's Telephone Number)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

ITEM 7.01. Regulation FD Disclosures.

On May 23, 2007 the Registrant issued the press release titled “Chembio and Infectious Disease Research Institute Collaborating on Development of Rapid Tests for Leishmaniasis and Leprosy” included herein as Exhibit 99.1.

On May 30, 2007 the Registrant issued the press release titled “Chembio Appoints Robert L. Aromando, Jr. Senior Vice President, Commercial Operations” included herein as Exhibit 99.2.

ITEM 9.01. Financial Statements and Exhibits

(d) Exhibits.

99.1 Press Release titled “[Chembio and Infectious Disease Research Institute Collaborating on Development of Rapid Tests for Leishmaniasis and Leprosy](#)” issued May 23, 2007.

99.2 Press Release titled “[Chembio Appoints Robert L. Aromando, Jr. Senior Vice President, Commercial Operations](#)” issued May 30, 2007.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K shall not be deemed “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing. This Current Report on Form 8-K does not constitute a determination of whether any information included herein is material.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: May 30, 2007

Chembio Diagnostics, Inc.

By: /s/ Lawrence A. Siebert
Lawrence A. Siebert
Chief Executive Officer



ChemBio and Infectious Disease Research Institute Collaborating on Development of Rapid Tests for Leishmaniasis and Leprosy

May 23, 2007 - Medford, NY and Seattle, WA - ChemBio Diagnostics, Inc. (OTCBB:CEMI) and the Infectious Disease Research Institute (IDRI) have entered into two research and development agreements for the development of rapid diagnostic tests for Leishmaniasis and Leprosy, two “neglected diseases” targeted by IDRI. The tests will be developed by ChemBio using ChemBio’s patented Dual Path immunoassay test platform (DPP™) and will incorporate IDRI proprietary antigens.

In preliminary studies conducted during the first quarter of 2007, ChemBio demonstrated superior analytical sensitivity on certain well characterized samples from patients with these diseases. These studies resulted in the decision by ChemBio and IDRI to enter into two Cooperative Research and Development Agreements to further these efforts.

IDRI, which has funding from the National Institutes of Health and the Bill and Melinda Gates Foundation for the development of vaccines and diagnostics for leishmaniasis, and from the American Leprosy Mission for similar activities in leprosy, actively partners with industrial organizations to achieve its goals of developing products to aid in the control of selected diseases.

Following completion of the prototype tests this year, the parties intend to then seek commitments for procurement of these products for affected populations globally. The leishmania parasite affects millions of people worldwide, while leprosy continues to be an important public health problem, with approximately 1 million new cases per year. Access to better diagnostic tools will be essential for control of these diseases.

ABOUT LEISHMANIASIS

Leishmaniasis is a widespread parasitic disease with frequent epidemics in the Indian subcontinent, Africa, and Latin America and is a World Health Organization priority for vaccine development. A complex of different diseases, Leishmania parasites cause fatal infections of internal organs, as well as serious skin disease. One of the most devastating forms of leishmaniasis is a disfiguring infection of the nose and mouth. The number of cases of leishmaniasis are increasing, and it is now out of control in many areas. Leishmaniasis is also on the rise in some developed countries, specifically southern Europe as a result of HIV infection. Available drugs are toxic, expensive, and require long-term daily injections. Leishmania are protozoan parasites that inhabit macrophages or the white blood cells of the immune system. The parasites are transmitted by the bite of small blood sucking insects (sand flies), which are difficult to control, as they inhabit vast areas of the planet. It is estimated that about 500,000 new cases of the visceral form (kala-azar or “the killing disease”) occur each year. Most of the deaths occur in children. Those with the cutaneous forms are often left permanently disfigured.

There are 12 million cases of leishmaniasis worldwide, two million new cases per year, 500,000 of which are the visceral form. Leishmaniasis causes hundreds of thousands deaths per year (70% are children).

ABOUT LEPROSY

Leprosy, or Hansen's disease, is a chronic infectious disease caused by the intra-cellular pathogen *Mycobacterium leprae* -- a bacterium that is related to the organism that causes tuberculosis (TB). The bacillus primarily grows within lesions in the cooler body areas such as the skin, limbs, eyes, and nasal cavity. The damage of the peripheral nerves leads to muscle weakness and atrophy, and numbness or loss of sensitivity to touch and heat in several areas of the skin. Viable leprosy bacilli are transmitted by droplets from the nose and mouth of infected persons. The stigma attached to leprosy has often caused those who contract the disease to be shunned by family, friends, and society. 1.6 billion people worldwide are exposed to leprosy, which is endemic in 24 countries. 500,000 new cases are found each year, that's over 1,300 cases every day. It is estimated that four to five million people already suffer from, or have deformities due to, leprosy.

Approximately 20 years ago, it became possible to treat leprosy. A multidrug therapy (MDT) comprised of several drugs given orally for a period of six to twenty four or more months may cure leprosy but can cause severe side effects. Although combination antibiotic therapy provided during the early stages of the disease reduces disease progression and spread, poor diagnostics and lack of access to regular health care mean that many who develop leprosy are treated only late in the disease, after disfigurement and transmission to others have already occurred.

ABOUT IDRI

The Infectious Disease Research Institute, Seattle, Washington, is a 501(c)(3) “non-profit biotech” that develops vaccines, diagnostics, and therapeutics for neglected diseases, including tuberculosis, leishmaniasis, leprosy, Chagas disease and others.

IDRI contact: Curt Malloy cmalloy@idri.org; 206-381-0883

ABOUT CHEMBIO

Chembio Diagnostics, Inc., a developer and manufacturer of rapid diagnostic tests for infectious diseases, is on the frontlines of the global battle against the AIDS pandemic. The Company has received marketing approval from the FDA for its SURE CHECK(R) HIV 1/2 and HIV 1/2 STAT-PAK(TM) rapid tests, marketed in the United States by Inverness Medical Innovations. The Company also manufactures rapid tests for veterinary Tuberculosis and Chagas Disease,

In March 2007 Chembio was issued a United States patent for the Dual Path Platform (DPP(TM)), a next generation lateral flow platform DPP has demonstrated significant advantages over currently available lateral flow methods, including increased sensitivity, sample flexibility, and multiplexing capabilities. Further information on the technology is available at <http://www.chembio.com/newtechnologies.html>.

Chembio contact: Matty Arce marce@chembio.com 631-924-1135 x123

Media Contact: Francesca Simone fsimon@stephensongroup.com 917-318-8776



**ChemBio Appoints Robert L. Aromando, Jr.
Senior Vice President, Commercial Operations**

May 30, 2007 - Medford, NY - ChemBio Diagnostics, Inc. (OTCBB:CEMI) has appointed Robert L. Aromando as its Senior Vice President, Commercial Operations. Mr. Aromando brings over 30 years of healthcare sales, marketing, business development and government affairs experience to ChemBio. In this new position at ChemBio, Mr. Aromando will lead the implementation of ChemBio's business plan for its recently patented Dual Path Platform (DPP™) point of care technology, and will also oversee all of ChemBio's other sales, marketing and business development activities.

Most recently Mr. Aromando was Managing Partner of K Street Associates, LLC, a lobbying and public policy consulting practice he established in 2006 that represents diagnostic and other healthcare companies. From 2001-2006, Mr. Aromando was Vice President of Marketing, Government Affairs and Public Policy for Bracco Diagnostics, a privately held global leader in medical imaging products with over \$1 billion in sales and over 3000 employees. Mr. Aromando was previously International Marketing Director for Hoffman La Roche (1991-1998), Director of Global Marketing of Covance Corporation (1998-2000), and President of American Bio Medica (2000-2001). In these positions, Mr. Aromando was significantly engaged in point of care diagnostics, primarily in drug testing. Earlier in his career, from 1984-1991, Mr. Aromando held sales and marketing positions with Diagnostic Technology and American Home Products, where his experience included the design and implementation of strategic marketing plans, OEM contracts and distribution agreements for a number of infectious disease diagnostic products and platforms.

Mr. Aromando has a BS in Immunology and Business from Mercy College, and a Wharton Executive Education Certificate. He is a registered lobbyist with the State of New Jersey and the United States House of Representatives and Senate.

Lawrence Siebert, Chairman and CEO of ChemBio, commented: "We welcome Bob Aromando and the broad range of experience that he brings to ChemBio as well as the confidence and enthusiasm he brings to achieving our objectives."

Robert Aromando, Senior Vice President of ChemBio commented: "This is a great opportunity for me personally and I look forward to working with an outstanding team at ChemBio as we bring our new technology to market."

ABOUT CHEMBIO

ChemBio Diagnostics, Inc., a developer and manufacturer of rapid diagnostic tests for infectious diseases, is on the frontlines of the global battle against the AIDS pandemic. The Company has received marketing approval from the FDA for its SURE CHECK(R) HIV 1/2 and HIV 1/2 STAT-PAK(TM) rapid tests, marketed in the United States by Inverness Medical Innovations. The Company also manufactures rapid tests for veterinary Tuberculosis and Chagas Disease,

In March 2007 ChemBio was issued a United States patent for the Dual Path Platform (DPP(TM)), a next generation lateral flow platform. DPP has demonstrated significant advantages over currently available lateral flow methods, including increased sensitivity, sample flexibility, and multiplexing capabilities. Further information on the technology is available at <http://www.chembio.com/newtechnologies.html>.

ChemBio contact: Matty Arce marce@chembio.com; 632-924-1135 x123